9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Estimated reading time: < 1 min

Condition

Cancer

Estimated Enrollment: 75

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 010124|01-C-0124|NCI-2792|CDR0000068615

Study First Received: July 11, 2001

Last Updated: March 14, 2012

Estimated Primary Completion Date: April 2008

Primary Outcome Measures:

Dose-limiting toxicities and maximum tolerated dose|Pharmacology and pharmacokinetics|Acetylation of histones in peripheral blood|Tumor response by CT scan every 12 weeks

Sponsors and Collaborators:

National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT00020579

Was this article helpful?
Views: 5